NCT04908514

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Aldeyra Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	ADX-629	ADX-629 administered orally twice daily (BID) for approximately 12 weeks.

Timeline

• Start date: 2021-05-07
• Primary completion: 2022-01-21
• Completion: 2022-01-21
• First posted: 2021-06-01
• Last updated: 2025-03-11
• Results posted: 2025-03-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study